Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.
收藏DataCite Commons2024-12-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005147/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.
提供机构：
Vivli
创建时间：
2020-01-15
